Back HCV Treatment

EASL 2015: Sofosbuvir + Pegylated Interferon/ Ribavirin Effective for Hard-to-Treat Genotype 3 HCV

A throwback regimen of sofosbuvir (Sovaldi), ribavirin, and pegylated interferon taken for 12 weeks cured 93% of patients with hepatitis C virus (HCV) genotype 3 -- substantially more than sofosbuvir plus ribavirin alone taken for 16 or 24 weeks, according to results from the BOSON study presented Saturday at the European Association for the Study of the Liver (EASL) 50th International Liver Congress in Vienna. Interferon-containing therapy for 3 months was described as "surprisingly well-tolerated."


Read more: